AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7670342 — intervention group
Group type: EXPERIMENTAL
Intervention: Millimetric electromagnetic radiation (MER) therapy using wavelengths of 6.4 and 7.1 mm on a YAVOR device for 10 sessions
Number of subjects: 54
Study 7670342 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific drugs without MER therapy)
Number of subjects: 54
Study 2111754 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant
Number of subjects: 15
Study 2111754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7004051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PGE2 (0.5 mg initially, followed by 1.0 mg every hour for up to 24 hours)
Number of subjects: 200
Study 7004051 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (starting at 5 mIU/min, increasing to 20 mIU/min)
Number of subjects: 200
Study 7004051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PGE2
Number of subjects: 200
Study 7004051 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 200
Study 7004051 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (PGE2 and oxytocin)
Number of subjects: 200
Study 31781890 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling cannulas drain of seroma (Group A)
Number of subjects: 86
Study 31781890 — intervention group
Group type: COMPARATOR
Intervention: Needle aspiration of seroma (Group B)
Number of subjects: 86
Study 31204104 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmetless tackling/blocking drills (WoH)
Number of subjects: 115
Study 31204104 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-level WoH participants
Number of subjects: 115
Study 31204104 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal training)
Number of subjects: 115
Study 28478996 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (risperidone, olanzapine, quetiapine)
Number of subjects: 9
Study 28478996 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 9
Study 28478996 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 9
Study 25526906 — intervention group
Group type: EXPERIMENTAL
Intervention: Daidzein (500 mg/kg concentrate)
Number of subjects: 14
Study 25526906 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 23648344 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (0.8 mg×kg(‐1)×d(‐1)) therapy
Number of subjects: 28
Study 21819161 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole-Mg 40 mg once daily for 8 weeks
Number of subjects: 636
Study 21819161 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole-Na 40 mg once daily for 8 weeks
Number of subjects: 636
Study 21819161 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole-Mg 40 mg once daily for 4 weeks
Number of subjects: 636
Study 21819161 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole-Na 40 mg once daily for 4 weeks
Number of subjects: 636
Study 19135834 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 746
Study 19135834 — intervention group
Group type: EXPERIMENTAL
Intervention: Newspaper advertising
Number of subjects: 746
Study 19135834 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed recruitment letters to patients with PAD
Number of subjects: 746
Study 19135834 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio advertising
Number of subjects: 746
Study 19135834 — intervention group
Group type: COMPARATOR
Intervention: Television advertising
Number of subjects: 746
Study 19135834 — intervention group
Group type: COMPARATOR
Intervention: Life Line Screening
Number of subjects: 746
Study 19135834 — intervention group
Group type: COMPARATOR
Intervention: Mailed postcards to older community dwelling men and women
Number of subjects: 746
Study 17876969 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth self-efficacy (SEPA) measures for physical activity
Number of subjects: 0
Study 17876969 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy efficacy (PEPA) measures for physical activity
Number of subjects: 0
Study 17876969 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in SEPA scales
Number of subjects: 0
Study 17876969 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial levels of PEPA-Parents and SEPA scales
Number of subjects: 0
Study 14550591 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine vaginal irrigation
Number of subjects: 176
Study 14550591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 10724056 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly directly observed preventive therapy with a $5 monetary incentive
Number of subjects: 118
Study 10724056 — intervention group
Group type: COMPARATOR
Intervention: Biweekly directly observed preventive therapy using a peer health adviser
Number of subjects: 118
Study 10724056 — intervention group
Group type: COMPARATOR
Intervention: Usual care at the tuberculosis clinic
Number of subjects: 118
Study 8956924 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 51
Study 8956924 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 51
Study 8956924 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of VGB and CBZ
Number of subjects: 51
Study 1551748 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 mg slow‐release co‐dergocrine mesylate administered once daily for 6 weeks
Number of subjects: 20
Study 1551748 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 mg slow‐release co‐dergocrine mesylate
Number of subjects: 20
Study 1551748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3873389 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral, nonabsorbable antibiotics (gentamicin + vancomycin + nystatin or neomycin + colistin + nystatin)
Number of subjects: 140
Study 3873389 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral, nonabsorbable antibiotics)
Number of subjects: 140
Study 3873389 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral, nonabsorbable antibiotics
Number of subjects: 140
Study 31618127 — intervention group
Group type: EXPERIMENTAL
Intervention: GC4419 90 mg
Number of subjects: 223
Study 31618127 — intervention group
Group type: EXPERIMENTAL
Intervention: GC4419 30 mg
Number of subjects: 223
Study 31618127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 29300737 — intervention group
Group type: EXPERIMENTAL
Intervention: HemoCue® wicking method
Number of subjects: 132
Study 29300737 — intervention group
Group type: EXPERIMENTAL
Intervention: HemoCue® gravity method
Number of subjects: 132
Study 29300737 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronto® DCI‐mini™
Number of subjects: 132
Study 27871280 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation therapy (n=55)
Number of subjects: 110
Study 27871280 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (n=55)
Number of subjects: 110
Study 24772445 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 107
Study 24772445 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 107
Study 23165580 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic dairy product containing Bifidobacterium BB12, Lactobacillus casei CRL 431 and fiber
Number of subjects: 102
Study 23165580 — intervention group
Group type: COMPARATOR
Intervention: Control yoghurt
Number of subjects: 102
Study 23165580 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic yoghurt
Number of subjects: 102
Study 23165580 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic dairy product
Number of subjects: 102
Study 20159245 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 909
Study 20159245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil
Number of subjects: 909
Study 20159245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 909
Study 20159245 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Budesonide, Nedocromil, Placebo)
Number of subjects: 909
Study 18612130 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron reduction (phlebotomy)
Number of subjects: 1277
Study 18612130 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1277
Study 16080282 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (FT) 3 g every 10 days for 6 months
Number of subjects: 317
Study 16080282 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) every 10 days for 6 months
Number of subjects: 317
Study 16080282 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (FT)
Number of subjects: 317
Study 16080282 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 317
Study 11821721 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nitrendipine
Number of subjects: 4695
Study 11821721 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 4695
Study 11821721 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 4695
Study 11821721 — intervention group
Group type: COMPARATOR
Intervention: Placebo for nitrendipine
Number of subjects: 4695
Study 11821721 — intervention group
Group type: COMPARATOR
Intervention: Placebo for enalapril
Number of subjects: 4695
Study 11821721 — intervention group
Group type: COMPARATOR
Intervention: Placebo for hydrochlorothiazide
Number of subjects: 4695
Study 9808110 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin group (n=15)
Number of subjects: 30
Study 9808110 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 30
Study 7702152 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative oral fluids (water)
Number of subjects: 95
Study 7702152 — intervention group
Group type: COMPARATOR
Intervention: Normal fasting regimen
Number of subjects: 95
Study 2694861 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms/kg
Number of subjects: 46
Study 2694861 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 46
Study 363484 — intervention group
Group type: EXPERIMENTAL
Intervention: Celestone Chronodose (subacromial injection)
Number of subjects: 180
Study 363484 — intervention group
Group type: EXPERIMENTAL
Intervention: Celestone Chronodose (gluteal injection)
Number of subjects: 180
Study 363484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 31779925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure reduction with diuretics
Number of subjects: 9361
Study 31779925 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure reduction with diuretics
Number of subjects: 9361
Study 31779925 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic use
Number of subjects: 9361
Study 29872803 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g high MW (HMW) barley β-glucan
Number of subjects: 30
Study 29872803 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g low MW (LMW) barley β-glucan
Number of subjects: 30
Study 29872803 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g low MW (LMW) barley β-glucan
Number of subjects: 30
Study 26439789 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakdown (BD) training
Number of subjects: 36
Study 26439789 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-load breakdown training
Number of subjects: 36
Study 26439789 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional resistance training
Number of subjects: 36
Study 26439789 — intervention group
Group type: COMPARATOR
Intervention: All groups (BD, heavy-load breakdown, traditional)
Number of subjects: 36
Study 24483133 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic surgery (SPLS)
Number of subjects: 230
Study 24483133 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery (CLS)
Number of subjects: 230
Study 23250715 — intervention group
Group type: EXPERIMENTAL
Intervention: Small head (28-32 mm) metal on polyethylene (MoP) articulation
Number of subjects: 49
Study 23250715 — intervention group
Group type: COMPARATOR
Intervention: Large head (44-54 mm) metal on metal (MoM) articulation
Number of subjects: 49
Study 21130977 — intervention group
Group type: COMPARATOR
Intervention: losartan 100 mg
Number of subjects: 13
Study 21130977 — intervention group
Group type: COMPARATOR
Intervention: isosorbide mononitrate (ISMN) 60 mg
Number of subjects: 13
Study 21130977 — intervention group
Group type: COMPARATOR
Intervention: losartan 100 mg + ISMN 15 mg
Number of subjects: 13
Study 21130977 — intervention group
Group type: COMPARATOR
Intervention: losartan 100 mg + ISMN 60 mg
Number of subjects: 13
Study 21130977 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study 17984166 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg per day
Number of subjects: 5011
Study 17984166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5011
Study 16121346 — intervention group
Group type: EXPERIMENTAL
Intervention: EGD plus EUS (EGD/EUS group)
Number of subjects: 105
Study 16121346 — intervention group
Group type: COMPARATOR
Intervention: EGD only (EGD group)
Number of subjects: 105
Study 11581232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 2 g iv bd
Number of subjects: 160
Study 11581232 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 2 g iv tds
Number of subjects: 160
Study 9699698 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills training
Number of subjects: 80
Study 9699698 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial occupational therapy
Number of subjects: 80
Study 8021762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 62
Study 8021762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 2691539 — intervention group
Group type: EXPERIMENTAL
Intervention: HPL bitewing device
Number of subjects: 30
Study 2691539 — intervention group
Group type: COMPARATOR
Intervention: Conventional freehand method
Number of subjects: 30
Study 2691539 — intervention group
Group type: COMPARATOR
Intervention: Rinn XCP instrument
Number of subjects: 30
Study 7931739 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a community physician, monthly 10‐minute work‐site counseling sessions including blood pressure readings, and personalized mailings
Number of subjects: 159
Study 7931739 — intervention group
Group type: COMPARATOR
Intervention: Physician referral only
Number of subjects: 159
Study 626273 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g single dose)
Number of subjects: 55
Study 626273 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four tablets)
Number of subjects: 55
Study 31532482 — intervention group
Group type: EXPERIMENTAL
Intervention: Online patient portal for CRC screening decision support program
Number of subjects: 0
Study 28732800 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid (TCA) 25%
Number of subjects: 9
Study 28732800 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid (TCA) 40%
Number of subjects: 9
Study 28732800 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenol/croton oil
Number of subjects: 9
Study 28732800 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9
Study 26559740 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using InGaAlP (660 nm-100 mW-4J/cm2) laser diode.
Number of subjects: 94
Study 26559740 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no treatment).
Number of subjects: 94
Study 26559740 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT).
Number of subjects: 94
Study 25226108 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition risk assessment using the Australian Nutrition Screening Initiative (ANSI)
Number of subjects: 3893
Study 25226108 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment using WHOQOL-BREF
Number of subjects: 3893
Study 25226108 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical function assessment using the Nottingham Extended Activities of Daily Living
Number of subjects: 3893
Study 25226108 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessment using the 15 item Geriatric Depression Scale
Number of subjects: 3893
Study 22888655 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation by 2 fractions of 6.5 Gy
Number of subjects: 333
Study 22888655 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation by 3 fractions of 6.5 Gy
Number of subjects: 333
Study 22888655 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation by 4 fractions of 6.5 Gy
Number of subjects: 333
Study 22888655 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple small fraction irradiation
Number of subjects: 333
Study 22888655 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation for breast cancer patients
Number of subjects: 333
Study 22888655 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation for prostate cancer patients
Number of subjects: 333
Study 22888655 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation for lung cancer patients
Number of subjects: 333
Study 22888655 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation for renal cancer patients
Number of subjects: 333
Study 22888655 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pain recurrence in irradiated area
Number of subjects: 333
Study 22888655 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended irradiation for breast and prostate cancer patients
Number of subjects: 333
Study 22888655 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended irradiation for lung and renal cancer patients
Number of subjects: 333
Study 19470154 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte transplantation (AC)
Number of subjects: 10
Study 19470154 — intervention group
Group type: COMPARATOR
Intervention: Subchondral drilling (SD)
Number of subjects: 10
Study 19470154 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum WF6 levels
Number of subjects: 10
Study 19470154 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum HA levels
Number of subjects: 10
Study 17894335 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of apomorphine hydrochloride for 5 days
Number of subjects: 5
Study 17894335 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion for 5 days
Number of subjects: 5
Study 17894335 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of apomorphine hydrochloride
Number of subjects: 5
Study 17894335 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of apomorphine hydrochloride and placebo
Number of subjects: 5
Study 15041714 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐275291 (1200 mg/day)
Number of subjects: 72
Study 15041714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 11585606 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of T enanthate i.m. weekly for 8 weeks (active group)
Number of subjects: 37
Study 11585606 — intervention group
Group type: COMPARATOR
Intervention: 200 mg of sodium chloride i.m. weekly for 8 weeks (placebo group)
Number of subjects: 37
Study 11585606 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg T enanthate i.m. bi-weekly for 8 weeks (hypogonadal group)
Number of subjects: 37
Study 9823478 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual n-back working memory task (n = 1, 2, 3)
Number of subjects: 8
Study 8008347 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitreous surgery (vitrectomy)
Number of subjects: 62
Study 8008347 — intervention group
Group type: COMPARATOR
Intervention: Observation (control)
Number of subjects: 62
Study 2478601 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape-slide series using a desensitization and modeling approach
Number of subjects: 28
Study 2478601 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate measurement
Number of subjects: 28
Study 2478601 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Melamed's scale
Number of subjects: 28
Study 2478601 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective dentist's evaluation
Number of subjects: 28
Study 177372 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam
Number of subjects: 52
Study 177372 — intervention group
Group type: COMPARATOR
Intervention: pivampicillin
Number of subjects: 52
Study 177372 — intervention group
Group type: COMPARATOR
Intervention: alternating treatment of pivmecillinam and pivampicillin
Number of subjects: 52
Study 28597308 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosted telephone follow-up after occupational rehabilitation program
Number of subjects: 213
Study 28597308 — intervention group
Group type: COMPARATOR
Intervention: Control group (no boosted follow-up)
Number of subjects: 213
Study 25721464 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized lifestyle and life skills intervention (12 weeks)
Number of subjects: 28
Study 25721464 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 28
Study 23851034 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 135
Study 23851034 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 135
Study 22101426 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention focusing on self-management, delivered by a clinical pharmacist, with structured education about COPD and management of its symptoms.
Number of subjects: 133
Study 22101426 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 133
Study 19897470 — intervention group
Group type: EXPERIMENTAL
Intervention: Any gastrointestinal infection in infancy
Number of subjects: 13089
Study 19897470 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalisation for gastrointestinal infection in infancy
Number of subjects: 13089
Study 19897470 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalisation for gastrointestinal infection in infancy or childhood
Number of subjects: 13089
Study 19453396 — intervention group
Group type: EXPERIMENTAL
Intervention: H5 live influenza vaccine (A/17/Duck/Potsdam/86/92 (H5N2)), administered intranasally in two doses 21 days apart.
Number of subjects: 0